Synopsis.
The protein kinase Tpl2 is activated by LPS, TNF and IL-1. Activation of the native Tpl2 complex by these agonists requires the IKK -catalysed phosphorylation of the p105/NF B1 subunit and is accompanied by the release of the catalytic subunit from both p105/NF B1 and another subunit ABIN2. Here we report that IL-1 activates the transfected Tpl2 catalytic subunit in an HEK293 cell line that stably expresses the IL-1 receptor, but does not express the protein kinase IRAK1. In these cells IL-1 does not activate IKK or induce the phosphorylation of p105/NF B1, and nor does the IKK inhibitor PS1145 prevent the IL-1-induced activation of transfected Tpl2. However, the IL-1-stimulated activation of transfected Tpl2 in IRAK1-null cells or activation of the endogenous Tpl2 complex in IRAK1-expressing cells, is suppressed by the protein kinase inhibitor PP2 by a mechanism that does not involve inhibition of Src family protein tyrosine kinases. The IL-1-stimulated activation of transfected Tpl2 is accompanied by its phosphorylation at Thr290 and Ser400 and by enhanced phosphorylation of Ser62, which we demonstrate are autophosphorylation events catalysed by Tpl2 itself. We further show that IL-1 triggers the dissociation of Tpl2 from co-transfected ABIN2 in IRAK1-null IL-1R cells, which is not suppressed by PP2 or by the inhibition of Tpl2 or IKK . These studies identify two new signaling events involved in activation of the native Tpl2 complex by IL-1. First, the IRAK1-, IKK -and PP2-independent dissociation of Tpl2 from ABIN2; second, the IRAK1and IKK -independent, but PP2-sensitive activation of the Tpl2 catalytic subunit. Keywords: innate immunity; Interleukin-1; IRAK1; NF B1; TNF; Tpl2;
Introduction.
The protein kinase Tpl2 (tumour progression locus 2), also called COT (Cancer Osaka Thyroid) plays a pivotal role in the production of tumour necrosis factor (TNF . Thus Tpl2-deficient mice fail to secrete TNF in response to bacterial lipopolysaccharide (LPS) [1] , and are protected against LPS-stimulated septic shock and TNF -induced inflammatory bowel disease [2] . Tpl2 mediates the production of TNF by activating the mitogen-activated protein kinase (MAPK) kinases 1 and 2 (MKK1, MKK2), which then activate extracellular signal-regulated kinases 1 and 2 (ERK1, ERK2) [1] . ERK1/ERK2 are required for the processing of pre-TNF to the secreted form of this pro-inflammatory cytokine [3] and contribute to the production of other inflammatory mediators [4, 5] .
Tpl2 is not only activated by LPS, but also by TNF and interleukin-1 (IL-1) [8] , so that pharmacological inhibition of this enzyme should suppress some of the actions of these cytokines, as well as their production. For these reasons, Tpl2 is an attractive target for the development of orally active drugs to treat chronic inflammatory diseases. Indeed, relatively specific pharmacological inhibitors of Tpl2 have been developed that suppress the LPS-stimulated production of TNF in human monocytes and block inflammatory responses in synoviocytes and blood [9] . The native Tpl2 complex comprises the catalytic subunit and two other proteins, termed p105 (also called NF B1) and A20-binding inhibitor of NF B 2 (ABIN2) [10] . The activation of Tpl2 by LPS [7, 11] or TNF requires the phosphorylation of p105 by I B kinase (IKK ) in primary mouse macrophages or mouse embryonic fibroblasts (MEFs), as phosphorylation was greatly reduced in IKK -deficient MEFs and suppressed by PS1145, an IKK inhibitor [7, 10] . The activation of Tpl2 in macrophages was accompanied by the ubiquitin-mediated proteolysis of p105, and the release of the Tpl2 catalytic subunit from both p105 and ABIN2. The Tpl2 catalytic subunit is expressed in cells as both a "long " form Tpl2 L (amino acid residues 1-467) and a "short" form Tpl2 S (residues 30-467), which result from the use of alternative initiating methionines at residues 1 and 30 [12] . The LPS-stimulated activation of Tpl2 that occurs within minutes correlates with the activation of Tpl2 L , which is then also rapidly degraded by the proteasome [7, 13] .
The presence of both p105 and ABIN2 is essential for Tpl2 stability and the level of expression of the Tpl2 catalytic subunit is extremely low in either p105-/- [11] or ABIN2-/- [14] primary mouse macrophages. However when re-transfected into p105-/-macrophages the Tpl2 catalytic subunit was not constitutively active and became active only after stimulation with LPS [15] . This experiment indicated that the activation of Tpl2 requires a second LPS-regulated step that is independent of the phosphorylation of p105 and its dissociation from Tpl2.
The Tpl2 catalytic subunit was reported to undergo phosphorylation at Thr290 when transfected into HEK293 cells and the mutation of this residue to Ala, prevented the LPS-stimulated activation of ERK1/ERK2 in transfected mouse RAW macrophages. These experiments suggested that the phosphorylation of Thr290 might be required for the activation of Tpl2 [16] . In addition, a catalytically inactive mutant of Tpl2 (Tpl2[K167M]) was reported to become phosphorylated at Thr290 in transfected 293 cells, suggesting that Thr290 phosphorylation did not occur as a result of autophosphorylation [16, 17] . The phosphorylation of Tpl2 at Thr290 was initially reported to be catalysed by IKK , based on siRNA knockdown studies and the use of high concentrations of the IKK inhibitor PS1145 [16] . However, subsequent work showed that lower concentrations of PS1145, but nevertheless sufficient to completely inhibit IKK did not affect the IL-1-stimulated phosphorylation of transfected Tpl2 at Thr290 [18] . Thus the IL-1-stimulated phosphorylation of Thr290 is catalysed by a protein kinase distinct from IKK .
LPS was reported to stimulate the phosphorylation of the endogenous Tpl2 catalytic subunit at Ser400 in primary mouse macrophages. LPS also stimulated Ser400 phosphorylation in an RAW mouse macrophage cell line that had been stably transfected with either wild type Tpl2 or a catalytically inactive mutant Tpl2[D270A] [15] . The phosphorylation of Ser400 was not impaired by BMS-345541 or IKK2 inhibitor IV, two different pharmacological inhibitors of IKK . aken together, these experiments suggested that the phosphorylation of Ser400 was not an autophosphorylation event in these cells and that it was catalysed by a protein kinase distinct from IKK . Unlike wild type Tpl2, the Tpl2[S400A] mutant failed to reconstitute the LPS-stimulated activation of MKK1 and ERK1/ERK2 when transfected into Tpl2-/-or p105-/-macrophages. These experiments suggested that Ser400 phosphorylation is required for the LPS-stimulated activation of the reconstituted Tpl2 complex in Tpl2-/-macrophages and the LPS-stimulated activation of the Tpl2 catalytic subunit in p105-/-macrophages [15] . However a truncated form of Tpl2 (Tpl2 T ), comprising amino acid residues 30-397, can be activated by IL-1 in transfected IL-1R cells [18] , indicating that IL-1 can activate Tpl2 T by a mechanism that is independent of the phosphorylation of Ser400. The sequence of Tpl2 T starts at the same residue as Tpl2 S but, like the oncogenic form originally identified in a human thyroid carcinoma [19] , it lacks the C-terminal 70 residues. Tpl2 T displays enhanced expression compared to Tpl2 L and Tpl2 S [20] .
Here, we demonstrate that IL-1 activates the transfected Tpl2 catalytic subunit and induces its dissociation from co-transfected ABIN2 by mechanisms that are independent of IRAK1 and IKK The activation of the transfected Tpl2 catalytic subunit, but not its dissociation from ABIN2, is suppressed by the protein kinase inhibitor PP2. These findings identify two further signalling events required for the activation of the Tpl2 complex by IL-1
Experimental.
Human IL-1 was expressed as a glutathione S-transferase (GST) fusion protein in E. coli, purified on glutathione-Sepharose, cleaved with PreScission proteinase to release IL-1 , and purified by gel-filtration on Superdex G200 by Dr. Gursant Kular in our Unit. A vector expressing GST-Phage phosphatase was transformed into E. coli (strain BL21s), the bacteria grown at 37 0 C until the absorbance at 600 nm was 0.4-0.6 and the expression of the phosphatase then induced by incubation for 20 h at 26 o C with IPTG (10 M). The bacteria were harvested and lysed, and the phosphatase purified on glutathione-Sepharose.
The Src family protein kinase inhibitor PP2 (4-amino-5-(4-chlorophenyl)-7-(tbutyl)pyrazolo [3,4-d] pyrmidine), the IKK inhibitor PS1145 (N-(6-chloro-9Hpyrido [3,4-b] indol-8-yl)-3-pyridinecarboxamide dihydrochloride) and staurosporine were purchased from Calbiochem, while the Tpl2 inhibitor called Compound-1 (C-1) [9] and SU6656 [21] were synthesised by Dr. Natalia Shpiro in our Unit.
Antibodies.
The peptides DERSKS*LLLS, KDLRGT*EIYMS and DQPRCQS*LDSAL, (where S* and T* are phosphoserine and phosphothreonine, respectively), corresponding to residues 57-67, 285-295, and 394-405 of human Tpl2, were synthesised by Dr Graham Bloomberg, University of Bristol, UK, coupled to both bovine serum albumin and keyhole limpet haemocyanin and injected into sheep at Diagnostics Scotland (Edinburgh, UK). The antibodies were affinity purified on CH-Sepharose to which the relevant phosphorylated peptide had been coupled covalently. The three phospho-specific antibodies recognising Tpl2 phosphorylated at Ser62 (S705B, bleed 2), Thr290 (S687B, bleed 2) and Ser400 (S027C, bleed 2) were used for immunoblotting at 1 g/ml. Phospho-specific antibodies were incubated for 1 h with the unphosphorylated form of the peptide immunogen (10 g/ml) to neutralise any antibodies that might recognise unphosphorylated Tpl2. A further antibody (S219C, bleed 2) that immunoprecipitates Tpl2 was made by injecting purified GST-Tpl2[30-397] (expressed in E. coli) into sheep. These antibodies were purified by affinity chromatography on GST-Tpl2-Sepharose and then freed from anti-GST antibodies by passage through GST-Sepharose. Antibodies that recognize the phosphorylated forms of IKK I B , p105, ERK1/ERK2, p38 MAPK, and p130CAS, or which recognise the unphosphorylated and phosphorylated forms of these proteins equally well, were from Cell Signalling Technologies, antibodies that recognise the phosphorylated forms of JNK1/JNK2 were from Biosource and an antibody that recognises IRAK1 was from Santa Cruz Biotechnology. Anti-FLAG and Anti-HA antibodies for immunoblotting and anti-FLAG-agarose and anti-HAagarose for immunoprecipitation were from Sigma, while rabbit, mouse and sheepspecific secondary antibodies conjugated to horseradish peroxidase were from Pierce.
DNA Cloning and Mutagenesis.
DNA encoding Tpl2 T (residues 30-397) (AY309013) was amplified from IMAGE EST 199903 (www.geneservice.co.uk) using the GC Rich PCR System (Roche). The resulting fragment was ligated into pCR2.1 (Invitrogen) and sequenced. pCR2.1-Tpl2[30-397] was digested with BamH1/ Not1 and ligated into the same sites in pCMV FLAG2 to produce pCMV FLAG2-Tpl2[30-397] for expressioion of the FLAG-fusion protein in mammalian cells. Vectors encoding FLAG-tagged Tpl2 L (amino acid residues 1-467) and FLAG-tagged Tpl2 S (amino acid residues 30-467) were produced in a similar manner. ABIN2 (NM_024309) was amplified from IMAGE EST 3632736 as described above and cloned into the BamH1 Not1 sites of pCMV HA to produced HA-tagged ABIN2 for expression in mammalian cells. Human IL-1 was amplified from IMAGE EST 3875593 using Expand HiFi Polymerase (Roche), then cloned into pCR2.1 (Invitrogen) and sequenced to completion. The resulting fragment was digested with BamH1 and Not1 and cloned into the same sites in pGEX6P-1 to create pGEX6P-1 IL-1 [117-268]. Sitedirected mutagenesis of Tpl2 was carried out using the Stratagene Quickchange protocol. The sequences of all clones were verified by the DNA Sequencing Service, in our Unit (www.dnaseq.co.uk).
Cell culture, transfection and lysis
Human embryonic kidney (HEK) 293 cells stably expressing the IL-1 receptor, termed IL-1R cells and IRAK1-null IL-1R cells (provided by Drs Xiaoxia Li and George Stark, Cleveland, USA) [22] were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% (v/v) foetal calf serum (FCS). Cells were transfected at 40-50% confluency using polyethyleneimine and 0.5 g DNA (Tpl2 T ), 1 g (Tpl2 L and Tpl2 S ) or 2 g (catalytically inactive mutants of Tpl2 L and Tpl2 L [T290A]). The FLAG-Tpl2 was expressed at a lower level than the endogenous Tpl2 in all the experiments reported in this paper. After 24 h, the medium was replaced with DMEM without serum and then left for 16 h before stimulation with 2.5 ng/ml IL-1 . All cells were maintained at 37°C in a 95% air and 5% CO 2 atmosphere and lysed in ice cold lysis buffer (50 mM Tris/HCl pH 7.5, 1 mM EDTA, 1 mM EGTA, 1 mM sodium orthovanadate, 10 mM sodium -glycerol-phosphate, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 0.27 M sucrose, 1% (v/v) Triton X-100, 0.1% (v/v) 2-mercaptoethanol, and Complete™ proteinase inhibitor cocktail (Roche: one tablet per 50 ml buffer)). Lysates were centrifuged at 13 000×g for 15 min at 4°C and the supernatants used immediately or snap frozen in liquid nitrogen and stored in aliquots at -20 °C until use. In experiments where protein kinase inhibitors were used, aliquots of these compounds dissolved at 10 mM in DMSO were added to the cell culture medium and an equivalent volume of DMSO was added to control incubations.
Immunoprecipitation of tagged-proteins and immunoblotting
FLAG-Tpl2 and HA-ABIN2 expressed in IL-1R cells were immunoprecipitated with anti-FLAG-agarose and anti-HA-agarose, respectively. To immunoprecipitate FLAG-Tpl2 or HA-ABIN2, 5 l of packed anti-FLAG-agarose or anti-HA-agarose beads were added to 0.5-1.0 mg of cell lysate protein and incubated for 60 min at 4°C on a shaking platform. After centrifugation for 15 sec at 13,000 x g, the supernatant was removed and the beads washed twice with 1 ml of lysis buffer. This was followed by two washes with 1 ml Buffer A (10 mM Tris-HCl pH 7.5, 2 mM EDTA and 0.2 % (v/v) NP-40) plus 150 mM NaCl, two washes with 1 ml Buffer A (plus 500 mM NaCl) and three washes with 1 ml 10 mM Tris-HCl pH 7.5. The immunoprecipitates were then denatured in lithium dodecyl sulphate (LDS) to release proteins from the antibody, and subjected to SDS-PAGE. After transfer to nitrocellulose, the membranes were immunoblotted using the ECL detection system (GE Healthcare).
Immunoprecipitation and assay of Tpl2
The endogenous Tpl2 in cell extracts was immunoprecipitated by coupling 1 g of Tpl2 antibody non-covalently to 5 l of Protein G-Sepharose beads. Cell extract (1-2 mg protein) was added, and after incubation for 2 h at 4 o C on a shaking platform, the beads were collected and washed as described above. The immunoprecipitated endogenous Tpl2 or immunoprecipitated FLAG-Tpl2 from transfection experiments were assayed and activity quantified as described previously for c-Raf [23] using a thermo-mixer to keep the beads agitated. In this two-step assay, Tpl2 is assayed by its ability to activate MKK1, which is then assayed by the activation of ERK2. The active ERK2 is then assayed by the phosphorylation of myelin basic protein. In some experiments, the Tpl2 immunoprecipitates were incubated for 30 min at 30 0 C with Phage phosphatase in 50 mM HEPES pH 7.5, 100 mM NaCl, 2 mM dithiothreitol, 0.01 % (w/v) Brij-35 pH 7.5 and 1 mM MnCl 2 in total volume 50 l. The reaction was agitated continuously and stopped by making the solution 1 mM in EGTA, 10 mM in NaF, 25 mM in -glycerolphosphate, 0.1 mM in Na 3 VO 4 . The immunoprecipitates were then washed five times with 1 ml of 10 mM Tris-HCl pH 7.5 and assayed for Tpl2 activity.
Results

IRAK1 is required for the IL-1-stimulated phosphorylation of p105 and the activation of the endogenous Tpl2 complex in IL-1R cells.
The activation of the transcription factor NF B and MAP kinases by IL-1 is known to require the IRAK4-catalysed activation of IRAK1, which leads to the activation of IKK and hence to the phosphorylation of its substrates I B and p105 (reviewed in [24] ). The phosphorylation of I B triggers proteasomal destruction thereby activating NF B, while the phosphorylation of p105 leads to the activation of Tpl2.
Consistent with the key role played by IRAK1 in the activation of IKK , the IL-1-stimulated phosphorylation of IKK and degradation of I B was greatly reduced and the phosphorylation of p105 abolished in IRAK1-null HEK293 cells that stably express the IL-1R ( Fig 1A) . The IL-1-stimulated activation of the endogenous Tpl2 complex ( Fig 1B) and the activation of ERK1/ERK2 ( Fig 1A) were also greatly reduced in the IRAK1-null cells, presumably as a result of the lack of phosphorylation of p105. The slight residual activation may be explained by the presence of low levels of the IRAK2 isoform in these cells (Xiaolia Li, personal communication). Consistent with the known role of IKK , the IKK inhibitor PS1145 suppressed the IL-1stimulated activation of the endogenous Tpl2 complex ( Fig 1B) and greatly reduced the activation of ERK1/ERK2 in the control IL-1R cells that express IRAK1 ( Fig 1C) . As expected, PS1145 also prevented the degradation of I B and the phosphorylation of p105 ( Fig 1C) , and did not affect the IL-1-stimulated phosphorylation (activation) of p38 MAP kinase and JNK ( Fig 1C) .
IL-1 activates the transfected Tpl2 catalytic subunit in IRAK1 null cells.
We have reported that IL-1 can induce the activation of a truncated form of the Tpl2 catalytic subunit (Tpl2 T ) in transfected IL-1R cells [18] , and similar results were obtained in the present study with the full length, long form of Tpl2 (Tpl2 L ) ( Fig  2A) . Surprisingly, IL-1 also induced a similar activation of transfected Tpl2 L in the IRAK1-null IL-1R cells (Fig 2A) , where IKK is not activated (Figs 1A, 2A and 2B), demonstrating that IL-1 activates Tpl2 L in IRAK1 null IL-1R cells by a mechanism that is independent of IRAK1, IKK and the phosphorylation of p105.
IL-1 induced a similar degree of activation of the transfected short form of Tpl2 (Tpl2 S ) and Tpl2 T in IRAK1-null IL-1R cells, but the kinetics of activation were quite different ( Fig S1) . Tpl2 L Tpl2 S and Tpl2 T were activated maximally at 15, 45 and 30 min after stimulation with IL-1, respectively, with activity declining thereafter, as judged by the activation of ERK1/ERK2 ( Fig S1) or direct measurements of Tpl2 activity (results not shown).
The Src inhibitor PP2 prevents the IL-1-induced activation and phosphorylation of the transfected Tpl2 catalytic subunit by a Src-independent pathway.
The IL-1-stimulated activation of ERK1/ERK2 in HeLa cells was reported to be suppressed by the inclusion of PP1 or PP2 in the culture medium [8] . These compounds were originally developed as small molecule inhibitors of the Src family of protein tyrosine kinases [25] . They do not affect the activity of Tpl2 T or its downstream target MAP kinase kinase 1 (MKK1) in vitro, even at 0.1 mM (Lorna Plater and Philip Cohen, results not shown). In the present study, we found that PP2 (25 M) suppressed the IL-1-stimulated activation of the endogenous Tpl2 complex ( Fig 3A) , as well as the activation of ERK1/ERK2 ( Fig 3B) in the IRAK1-expressing IL-IR cells. Importantly, PP2 did not prevent the IL-1-induced degradation of I B or the phosphorylation of p105 ( Fig 3B) , showing that PP2 had not exerted its effect by inhibiting the activation or activity of IKK . PP2 also did not affect the IL-1stimulated phosphorylation (activation) of p38 MAPK and JNK ( Fig 3B) . To investigate whether PP2 inhibited the activation of Tpl2 by a Src-dependent mechanism we studied the phosphorylation of p130CAS, which is phosphorylated at Tyr410 by Src family members [26] . The phosphorylation of p130CAS was completely suppressed at 1.0 M PP2 ( Fig 3B) , a concentration that had no effect on the IL-1 stimulated activation of the endogenous Tpl2 complex ( Fig 3A) or the activation of ERK1/ERK2 ( Fig 3B) . Indeed, further studies showed that PP2 prevented the phosphorylation of p130CAS with an IC 50 below 0.2 M ( Fig 3C) . Similar results were obtained in IRAK1-null IL-1R cells, PP2 suppressing the IL-1stimulated activation of Tpl2 L Tpl2 S and Tpl2 T ( Fig 4A) and consequent activation of ERK1/ERK2 ( Fig 4B) at 25 M but not 1 M PP2. These results suggested that PP2 exerts its effect on the IL-1-stimulated activation of Tpl2 by a Src-independent pathway. Similar results were obtained with the structurally unrelated Src inhibitor SU6656, which blocked the activation of p130CAS at concentrations that did not affect the IL-1-stimulated activation of transfected Tpl2 in IRAK1-null cells (Figs S2A and S2B). These results confirmed that Src does not mediate the IL-1stimulated activation of the Tpl2 catalytic subunit.
Phosphorylation of the Tpl2 catalytic subunit during activation by IL-1.
We have reported that the IL-1-stimulated activation of transfected Tpl2 T is accompanied by its phosphorylation at Ser62 and Thr290 in IRAK1-expressing IL-1R cells [18] . Here, we found that IL-1 also stimulated the phosphorylation of transfected Tpl2 T at these two sites in IRAK1-null IL-1R cells, and that IL-1 also induced the phosphorylation of Tpl2 L and Tpl2 S at Ser400, as well as at Ser62 and Thr290 ( Fig 5) . Importantly, PP2 prevented the IL-1-stimulated phosphorylation of Tpl2 at Thr290 and Ser400 and reduced the phosphorylation of Ser62 to the basal level observed in the absence of IL-1 stimulation ( Fig 5) .
Evidence that the phosphorylation of Ser62, Thr290 and Ser400 are autophosphorylation events.
To investigate whether the phosphorylation of Tpl2 L and Tpl2 T was catalysed by a distinct protein kinase(s) or by Tpl2 itself, we transfected IRAK1-null cells with the catalytically inactive mutants Tpl2[D270A] and Tpl2[K167R]. As expected, these mutants displayed no activity, even after stimulation with IL-1 ( Fig S3) and were unable to restore IL-1-stimulated activation of ERK1/ERK2 to IRAK1-null IL-1R cells (Fig 6, top panel) . Moreover, in contrast to wild type Tpl2, IL-1 was unable to enhance the phosphorylation of Ser62, or induce any phosphorylation of Thr290 or Ser400 in either of the catalytically inactive mutants (Fig 6, bottom three panels) . This suggested that the phosphorylation of all three residues was catalysed by Tpl2 itself, after it had been activated. In contrast, the basal phosphorylation of Ser62 in unstimulated cells was unaffected, demonstrating that it is catalysed by a distinct protein kinase (Fig 6, middle panel) .
To investigate further whether Tpl2 was really capable of autophosphorylation at Ser62, Thr290 and Ser400, we immunoprecipitated transfected Tpl2 L from the lysates of control and IL-1-stimulated IRAK1-null IL-1R cells. These preparations, which were phosphorylated at Ser62 or Ser62, Thr290 and Ser400, respectively ( Fig  7A, lanes 1 and 2) were then incubated with the protein phosphatase encoded by phage , which led to the dephosphorylation of all three sites ( Fig 7A, lanes 5 and 6) . Incubation of the phosphatase-treated Tpl2 L immunoprecipitates with MgATP led to the rephosphorylation of Ser62 (Tpl2 L from control cells) or Ser62, Thr290 and Ser400 (Tpl2 L from IL-1-stimulated cells) ( Fig 7A, lanes 7 and 8) . The rephosphorylation of Ser62, Thr290 and Ser400 by Tpl2 L immunoprecipitates from IL-1-stimulated cells was prevented by Compound-1 (C-1) ( Fig 7A, lane 10) , a cellpermeable inhibitor of Tpl2 [9] , indicating that activated Tpl2 is indeed capable of autophosphorylation at Thr290 and Ser400. However, the rephosphorylation of phosphatase-treated Tpl2 L was unaffected by PP2 ( Fig 7A, lane 12) , consistent with the failure of this compound to inhibit Tpl2 activity in vitro, and indicating that it prevents the IL-1-stimulated activation of Tpl2 by targeting a more upstream component of the signalling pathway.
The finding that the inactive Tpl2 L became rephosphorylated only at Ser62 upon incubation with Mg-ATP ( Fig 7A, lane 7) , suggested that it was contaminated with a protein kinase distinct from Tpl2 L that phosphorylates Ser62 in vitro. To investigate this possibility we used staurosporine, a potent inhibitor of many protein kinases, which we have found does not inhibit Tpl2. Staurosporine prevented the phosphorylation of Ser62 by the inactive Tpl2 L immunoprecipitates from control cells (Fig 7B, compare lanes 5 and 6) , but had no effect on the phosphorylation of Ser62, Thr290 and Ser400 by the active Tpl2 immunoprecipitates from IL-1-stimulated cells (Fig 7B, compare lanes 7 and 8) . These experiments established that Tpl2 catalyses the autophosphorylation of Ser62, Thr290 and Ser400 and confirmed that Ser62 phosphorylation by inactive Tpl2 immunoprecipitates is catalysed by a distinct protein kinase.
The phosphorylation of Ser62 by inactive Tpl2 immunoprecipitates was prevented by C-1 ( Fig 7A, lane 9) , showing that the binding of C-1 to Tpl2 prevents the phosphorylatiion of Ser62 by the contaminating protein kinase.
Site directed mutagenesis of the phosphorylation sites on Tpl2.
The incubation of Tpl2 immunoprecipitates from IL-1-stimulated cells with phage phosphatase had little effect on the ability of Tpl2 to activate MKK1 ( S4). However, as the phosphatase-treated Tpl2 became re-phosphorylated at Ser62, Thr290 and Ser400 within minutes of incubation with Mg-ATP (results not shown), this presumably occurs during the standard assay of Tpl2 making it impossible to assess whether the phosphorylation of these sites is required for the activation of MKK1. To address this issue we therefore mutated these sites to Ala and studied whether the mutant enzymes could be activated by IL-1 in transfected IRAK1-null cells.
The mutation of Ser400 to Ala only decreased the IL-1-stimulated activation of Tpl2 L slightly, while the mutation of Ser62 to Ala reduced activation by 40-50% ( Fig 8A) . In contrast, the mutation of Thr290 to Ala in Tpl2 L virtually abolished the activation of MKK1 by Tpl2 in vitro ( Fig 8A) as well as the IL-1-stimulated activation of ERK1/ERK2 in transfected cells ( Fig 8B) . Interestingly, the mutation of both Ser62 and Ser400 to Ala prevented the IL-1-stimulated phosphorylation of Thr290 ( Fig 8B) and the activation of Tpl2 (Fig 8A) . Taken together, these results suggest that the autophosphorylation of Tpl2 at Thr290 may be needed for Tpl2 to activate MKK1.
Although the mutation of Thr290 to Ala prevented Tpl2 from activating MKK1, it did not prevent the autophosphorylation of Tpl2 at Ser62 or Ser400 ( Fig  8B) . Taken together, these experiments demonstrate that the phosphorylation of Thr290 is not required for the IL-1-induced conformational change that allows Tpl2 to autophosphorylate, although it may be needed for Tpl2 to phosphorylate and activate MKK1.
We also carried out mutagenesis studies on Tpl2 T (Figs S5A and S5B ). This species was activated by IL-1 similarly to Tpl2 L (Fig S1B) , demonstrating that the phosphorylation of Ser400 or any other residue in the C-terminal tail between amino acid residues 398 and 467 is not required for the IL-1-induced conformation change that activates the Tpl2 catalytic subunit. As reported previously [18] , the mutation of Ser62 to Ala only reduced the IL-1-stimulated activation of Tpl2 T by 40% ( Fig S5A) , demonstrating that IL-1 can still activate a form of the Tpl2 catalytic subunit in which neither Ser62 nor Ser400 are phosphorylated. Similar to Tpl2 L , the mutation of Thr290 to Ala prevented the IL-1-stimulated activation of Tpl2 T , but in contrast to Tpl2 L , it also prevented the phosphorylation of Ser62 ( Fig S5B) .
The mutagenesis experiments presented in Fig 8B also established the specificity of the phospho-specific antibodies used in these experiments. The mutation of Ser62 to Ala prevented recognition of this site by the anti-phospho-Ser62 antibody without affecting the IL-1 stimulated phosphorylation of Thr290 or Ser400. Similarly, mutagenesis of Thr290 to Ala prevented recognition by the anti-phospho-Thr290 antibody without affecting the IL-1-stimulated phosphorylation of Ser62 or Ser400, while mutagenesis of Ser400 to Ala prevented recognition by the antiphospho-Ser400 antibody without affecting the phosphorylation of Ser62 or Thr290 (Fig 9B) .
IL-1 triggers the dissociation of Tpl2 and ABIN2 in transfected IL-1R cells.
The activation of Tpl2 is associated with its release from ABIN2, as well as from p105 [10] . To investigate whether the IL-1-stimulated dissociation of Tpl2 from ABIN2 was regulated independently of the phosphorylation of p105, we cotransfected DNA vectors encoding both ABIN2 and the Tpl2 catalytic subunit into IRAK1-null IL-1R cells followed by stimulation with IL-1. These experiments showed that IL-1 induced the dissociation of Tpl2 L from ABIN2 (Figs 9A and 9B ). Prior incubation of the cells with Compound-1 ( Fig 9A) or PP2 ( Fig 9B) did not prevent dissociation, indicating that the dissociation of these proteins was independent of Tpl2 activity or its activation. Similar results were obtained when Tpl2 T was used instead of Tpl2 L (results not shown).
Discussion.
It is well established that the activation of Tpl2 in macrophages by LPS or TNF requires the IKK -catalysed phosphorylation of the p105 regulatory subunit of the Tpl2 complex, and that it is accompanied by the release of the Tpl2 catalytic subunit from both p105 and ABIN2 [7, 13] . Here, we show that the activation of Tpl2 by IL-1 in IL-1R cells also requires the activation of IKK , because it is blocked by the IKK inhibitor PS1145 (Figs 1B and 1C) . However, the IKK -catalysed phosphorylation of p105 is not sufficient for activation and another signaling pathway is needed to activate the Tpl2 catalytic subunit. This second pathway does not require the presence of the IRAK1 protein or the IKK -catalysed phosphorylation of p105 (Figs 2 and S1), but is suppressed by PP2, a compound that does not affect IKK activity or the phosphorylation of p105 (Fig 4) . This pathway appears to be physiologically relevant because the IL-1-stimulated activation of the endogenous Tpl2 complex in IRAK1-expressing IL-1R cells (Fig 3A) , like the activation of the transfected catalytic subunit in IRAK1-null cells (Fig 4) , is suppressed by PP2. Moreover, we have found that IL-1 induces the dissociation of the Tpl2 catalytic subunit from co-transfected ABIN2 and that this is also independent of IRAK1 (Fig 9) or the activation of IKK However in contrast to the activation of the Tpl2 catalytic subunit, the IL-1-induced dissociation of Tpl2 from ABIN2 is not suppressed by PP2, and it is also independent of the activation or activity of Tpl2. Our results suggest that three different signaling events are involved in the release and activation of the Tpl2 catalytic subunit (Fig 10) . Whether these events occur in the sequence depicted in the figure or in a different order is unknown at the present time.
We studied the ability of IL-1 to activate different forms of the Tpl2 catalytic subunit following their transfection into IRAK1-null IL-1R cells. These experiments revealed that IL-1 activated Tpl2 L and Tpl2 S (the forms of Tpl2 that are present in vivo), as well as the C-terminally truncated species Tpl2 T , but at different rates ( Fig  S1) . Tpl2 L was activated most rapidly, consistent with earlier reports that the activation of this species underlies the initial rapid activation of ERK1/ERK2 in cells [7, 13] . Interestingly, the activation of Tpl2 S was much slower than Tpl2 L , raising the possibility that it might play a role in maintaining a low level of activation of ERK1/ERK2 after Tpl2 L has been inactivated by proteasomal destruction [7, 13] .
PP2 was originally developed as an inhibitor of the Src family of protein tyrosine kinases, but the concentrations of PP2 needed to prevent the IL-1-stimulated activation of Tpl2 were much higher than those required to suppress phosphorylation of p130CAS, a known physiological substrate of Src (Fig 3) . Moreover SU6656, a structurally unrelated Src inhibitor suppressed the phosphoryation of p130CAS without affecting the IL-1-stimulated activation of Tpl2 (Figs S2). Thus the involvement of Src family kinases in the activation of the Tpl2 catalytic subunit is excluded, suggesting that PP2 might exert its effect by inhibiting another protein kinase. PP2 does not inhibit Tpl2 activity in vitro, but does inhibits some other protein tyrosine kinases, such as the Bruton's tyrosine kinase and the Ephrin receptors A2 and B3 (Jennifer Bain, Matthew Elliott and Philip Cohen, unpublished work) and serine/threonine-specific protein kinases, such as CK1 [27] and Receptor Interacting Protein 2 (RIP2) [27] . However, the possibility that PP2 might exert its effect by binding to a non-kinase target cannot be excluded at this stage.
The IL-1-stimulated activation of transfected Tpl2 in IRAK1-null cells was accompanied by the phosphorylation of Thr290 and Ser400 and the enhanced phosphoryation of Ser62 ( Fig 5) . Under these conditions, the phosphorylation of these sites appears to result from autophosphorylation catalysed by Tpl2 itself, because two different catalytically inactive mutants did not become phosphorylated in response to IL-1 (Fig 6) . Moreover, Tpl2 that had been immunoprecipitated from IL-1-stimulated cells was able to phosphorylate all three sites in vitro ( Fig 7A) , and the phosphorylation of these sites was prevented by the Tpl2 inhibitor Compound-1. We have found that Compound-1 inhibits Tpl2 with an IC50 of 40 nM in vitro but at a concentration of 1 M has little effect on 70 other protein kinases tested (Jennifer Moran and Philip Cohen, unpublished results). These studies indicate that Compound-1 is a relatively selective inhibitor of Tpl2, although we cannot exclude the possibility that it inhibits other protein kinases that have not yet been tested.
Our mutagenesis studies demonstrated that the mutation of Ser62 or Thr290 or Ser400 does not prevent the IL-1-stimulated conformational change that activates the Tpl2 catalytic subunit, because the singly mutated species are still capable of autophosphorylation ( Fig 7B) . However, the mutation of Thr290 to Ala, or the combined mutation of Ser62 and Ser400 to Ala that prevents the phosphorylation of Thr290, does prevent Tpl2 from activating MKK1 ( Fig 8A) . These results suggest that the autophosphorylation of Tpl2 at Thr290 is required for the activation of MKK1, although not for the autophosphorylation of Ser62 and Ser400 (Fig 8B) . The three dimensional structure of Tpl2 has not yet been solved, but the region of the "activation loop" in which Thr290 is located is known to be important for the interaction of other protein kinases with their substrates, such as protein kinase B (PKB) [28] . Alignment of the activation segment of Tpl2 with that of PKB shows that they are very similar, with Thr290 of Tpl2 aligning with Thr313 of PKB. Thr313 is very close to where a peptide corresponding to the phosphorylation site on GSK3 binds to PKB, and could account for how the phosphorylation of Thr290 enables Tpl2 to activate MKK1 (David Barford, personal communication).
In summary, our results support the view that the IL-1 stimulated phosphorylation of Tpl2 at Thr290 and Ser400 and its enhanced phosphorylation of Ser62 are autophosphorylation events that are a consequence of the IL-1-stimulated conversion of the Tpl2 catalytic subunit to an active conformation, the autophosphorylation of Thr290 probably being required for Tpl2 to interact with and phosphorylate MKK1 (Fig 10) . However, further work is clearly needed to elucidate how IL-1 converts the catalytic subunit to the active conformation that is capable of autophosphorylation, which is independent of Thr290 phosphorylation.
Our finding that catalytically inactive mutants of Tpl2 do not become phosphorylated at Thr290 in response to IL-1 differs from earlier studies in which the catalytically inactive mutant Tpl2[K167M] was reported become phosphorylated at Thr290 in transfected HEK293 cells [16, 17] . The reasons for the discrepancy with our data are unclear. It has also been reported by others that the transfection of DNA encoding Tpl2[S400A] into Tpl2-/-macrophages did not restore the LPS-stimulated activation of ERK1/ERK2 to these cells [15] , suggesting a key role for Ser400 in the activation of the native Tpl2 complex. For example, it may facilitate the dissociation of Tpl2 from p105. It was also reported that LPS stimulates the phosphorylation of the catalytically inactive Tpl2 L [D270A] at Ser400 in RAW mouse macrophages [15] , suggesting that an LPS-stimulated Ser400 kinase, distinct from Tpl2, phosphorylates this site. This contrasts with the present study in which this catalytically inactive mutant did not become phosphorylated at Ser400 when transfected IRAK1-null cells were stimulated by IL-1 (Fig 6) . The apparent discrepancy between these two studies could be explained if the LPS-stimulated phosphorylation of Tpl2[D270A] at Ser400 was catalysed by the endogenous Tpl2 catalytic subunit in transfected RAW cells, which would be present and activated under these conditions. Alternatively, LPS may activate a Ser400 kinase in RAW macrophages that is not expressed or not activated by IL-1 in IL-1R cells.
Figure legends Figure 1. Components of IL-1-stimulated signaling pathways that are dependent on the presence of IRAK1 and the activity of IKK in IL-1R cells (A)
Wild type IL-1R cells (IRAK1+/+) and IRAK1-null IL-1R cells (IRAK1-/-) were serum starved for 16 h in DMEM, before stimulation with 2.5 ng/ml IL-1 for the times indicated. Following cell lysis and SDS-PAGE, immunoblotting was carried out with antibodies that recognise IRAK1, IKK phosphorylated at Ser180 (IKK ) and Ser181 (IKK ), I B , p105 phosphorylated at Ser933 (p-p105), the phosphorylated Thr-Glu-Tyr motif of ERK1 and ERK2 (p-ERK1,p-ERK2) and all forms of ERK1/ERK2. The IL-1-induced "disappearance" of IRAK1 results from its conversion to a variety of polyubiquitylated species [29] . (B) The experiment was carried out as in A except that, where indicated the serum starved cells were incubated for 60 min without or with 15 M PS1145, prior to stimulation for 15 min with 2.5 ng/ml IL-1. Following cell lysis, the endogenous Tpl2 was immunoprecipitated from 1mg of cell extract protein with 1 g of anti-Tpl2. Protein G Sepharose (15 l of packed beads) was added and, after mixing for 1 h, the beads were collected, washed and assayed for Tpl2 activity. The results are shown + SD for three different immunoprecipitations from one experiment and expressed at Units of activity per mg of cell lysate protein. Similar results were obtained in two other independent experiments. (C) Wild type IL-1R cells were serum starved for 16 h in DMEM, then incubated for 1h in the absence (-) or presence (+) of 15 M PS1145. After stimulation for 15 min with 2.5 ng/ml IL-1, 25 g of cell extract protein was denatured in SDS, subjected to SDS-PAGE, transferred to nitrocellulose and immunoblotted with the antibodies in (A) plus further antibodies that recognise the phosphorylated Thr-Pro-Tyr motif of JNK1/JNK2 (p-JNK1/p-JNK2), and the phosphorylated Thr-Gly-Tyr motif of p38 MAP kinase (p-p38 MAPK). As a loading control, the same lysate was also immunoblotted with an antibody that recognises the phosphorylated and unphosphorylated forms of p38 MAP kinase equally well.
Figure 2. The IL-1-stimulated activation of transfected Tpl2 L is independent of the presence of IRAK1 and the activity of IKK .
(A) DNA encoding FLAG-Tpl2 L was transfected into wild type IL-1R cells (+) or IRAK1 null IL-1R cells (-). After 24 h, the cells were incubated for a further 16 h in DMEM without serum and then for 1h with (+) or without (-) 15 M PS1145 before stimulation for 15 min with (+) or without (-) 2.5 ng/ml IL-1. Following cell lysis, the transfected Tpl2 was immunoprecipitated from 0.5 mg of cell extract protein anti-FLAG-agarose beads. The beads were collected by centrifugation and then washed and assayed for Tpl2 activity. The results are shown + SD for three different immunoprecipitations from one experiment and expressed at Units of activity per mg of cell lysate protein. Similar results were obtained in two other independent experiments. (B) The experiment was carried out as in A using only the IRAK1-null cells. 25 g of cell lysate protein was subjected to immunoblotting with the antibodies used in Fig 1A and with anti-FLAG (FLAG) to detect the expression of the transfected FLAG-Tpl2 L .
Figure 3. PP2 inhibits the IL-1-stimulated activation of endogenous Tpl2 in IRAK1+/+ IL-1R cells. (A)
IL-1R cells were serum starved for 16 h, incubated with the indicated concentrations of PP2, stimulated for 15 min with (+) or without (-) IL-1 and the endogenous Tpl2 immunoprecipitated and assayed as in Fig 1B. (B) 25 g of cell lysate protein from A were subjected to SDS-PAGE, transferred to a nitrocellulose membrane and immunoblotted with the antibodies in Figs 1A and 1C , as well as with an antibody that recognises p130CAS phosphorylated at Tyr410 (p-p130CAS). (C) IRAK1-null IL-1R cells were serum starved for 16 h in DMEM, then incubated for 1 h with the indicated concentrations of PP2 prior to cell lysis (no stimulation with IL-1). 25 g of cell extract protein was immunoblotted with antibodies that recognise the phosphorylated forms of p130CAS (p-p130CAS) and all forms of ERK1/ERK2.
Figure 4. Effect of Src family kinase inhibitors on the IL-1-stimulated activation of transfected Tpl2 in IRAK1-null IL-1R cells.
(C) IRAK1-null IL-1R cells were transfected with DNA encoding FLAG-Tpl2 L . FLAG-Tpl2 S or FLAG-Tpl2 T . After 24 h, the cells were serum-starved in DMEM for a further 16 h, then incubated for 60 min with the indicated concentrations of PP2, and then for a further 15 min with (+) or without (-) 2.5 ng/ml IL-1. After cell lysis, FLAG-Tpl2 was immunoprecipitated from 0.5 mg cell extract protein with anti-FLAG-coupled-agarose beads and assayed for Tpl2 activity as in Fig 2A. The results are shown + SD for three different immunoprecipitations from one experiment and expressed as Units of activity per mg of cell lysate protein. Similar results were obtained in another independent experiment. (B) 25 g of cell lysate protein from A were subjected to SDS-PAGE, transferred to a nitrocellulose membrane and immunoblotted with antibodies that recognise the phosphorylated forms of ERK1/ERK2 and with anti-FLAG to detect the transfected Tpl2. The experiment was carried out using IRAK1-null IL-1R cells as in Fig 4A after transfection with DNA encoding the three forms of Tpl2. Following cell lysis, FLAG-Tpl2 was immunoprecipitated from 0.5 mg cell extract protein with anti-FLAG beads, After release from the anti-FLAG beads by denaturation in SDS, the samples were subjected to SDS-PAGE, transferred to a PVDF membrane and immunoblotted with antibodies that recognise the phosphorylated forms of ERK1/ERK2 and Tpl2 phosphorylated at Ser62, Thr290, and Ser400, respectively. The same membrane was also immunoblotted with anti-FLAG as a loading control. The positions at which FLAG-Tpl2 L , FLAG-Tpl2 S and FLAG-Tpl2 T migrate are denoted by L, S and T. (A) IRAK1-null IL-1R cells were transfected with the indicated DNA constructs and, after 24 h, serum-starved in DMEM for a further 16 h. The cells were then stimulated for 15 min with (+) or without (-) 2.5 ng/ml IL-1. Following cell lysis, FLAG-Tpl2 L was immunoprecipitated from 1.0 mg of cell extract with anti-FLAG agarose beads and assayed for activity as in Fig 2A (B) the immunoprecipitates from A were denatured in LDS, subjected to SDS-PAGE and immunoblotted with the antibodies used in Fig 5.   Figure 9 . The IL-1-stimulated dissociation of ABIN2 from Tpl2 in IRAK1-null IL-1R cells does not require Tpl2 activity. (A) DNA encoding wild type (WT) FLAG-Tpl2 L or the indicated Tpl2 mutants were co-transfected into IRAK1-null IL-1R cells with HA-ABIN2. After 24 h, the cells were serum-starved in DMEM for 16 h, incubated for 60 min without (-) or with (+) 10 M Compound-1 (C-1), then stimulated for 15 min with (+) or without (-) 2.5 ng/ml IL-1. Following cell lysis, 25 g of cell extract protein was immunoblotted to detect the phosphorylated forms of ERK1/ERK2 (p-ERK1, p-ERK2). FLAG-Tpl2 or HA-ABIN2 were immunoprecipitated (IP) from a further 1 mg of cell extract protein using anti-FLAGagarose or anti-HA-Protein G-Sepharose, respectively. The beads were washed and bound proteins released from the antibodies with 0.1% LDS, subjected to SDS-PAGE and immunoblotted with anti-FLAG to detect Tpl2 and anti-HA to detect ABIN2. The immunoprecipitated Tpl2 was also immunoblotted with the antibodies used in Fig  6 to detect phosphorylation at Ser62, Thr290 and Ser400. (B) The experiment was carried out as in A except that only wild type Tpl2 L was used and PP2 replaced Compound-1. The native form of Tpl2 in unstimulated cells is an inactive heterotrimer comprising the catalytic subunit complexed with ABIN2 and p105. Its activation requires IRAK1 and the PS1145-sensitive, IKK -catalysed phosphorylation of p105, which leads to the release of p105 from Tpl2. IL-1 also induces the dissociation of ABIN2 and activates the Tpl2 catalytic subunit by pathways that do not require IRAK1 or the IKK -catalysed phosphorylation of p105. The IL-1 stimulated activation of the endogenous Tpl2 in IL-1R cells or the transfected Tpl2 catalytic subunit in IRAK1null cells is suppressed by PP2, a compound that does not affect the activation of IKK or the phosphorylation of p105. The PP2-sensitive component is not a member of the Src family of protein tyrosine kinases, but may be another protein kinase designated here as protein kinase X (PKX). The IL-1-stimulated conversion of the Tpl2 catalytic subunit to an active conformation is followed by its autophorylation at Ser62, Thr290 and Ser400. The autophosphorylation of Thr290 appears to be required for Tpl2 to phosphorylate and activate MKK1. For simplicity, the three signaling pathways involved in the activation of the Tpl2 complex are depicted as occurring sequentially, but do not necessarily takes place in this order in vivo. A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law. A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law. A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
